End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
15,660
KRW
|
+11.22%
|
|
-2.12%
|
+74.97%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
285,589
|
246,384
|
828,302
|
470,053
|
357,178
|
276,775
|
Enterprise Value (EV)
1 |
289,300
|
245,261
|
818,387
|
467,030
|
375,127
|
316,828
|
P/E ratio
|
44.9
x
|
29
x
|
129
x
|
24.8
x
|
28.7
x
|
82.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.74
x
|
1.97
x
|
6.23
x
|
3.5
x
|
2.28
x
|
1.79
x
|
EV / Revenue
|
2.78
x
|
1.96
x
|
6.15
x
|
3.47
x
|
2.39
x
|
2.05
x
|
EV / EBITDA
|
18.3
x
|
12.1
x
|
37.5
x
|
25.1
x
|
14.7
x
|
29.1
x
|
EV / FCF
|
31.6
x
|
-75.9
x
|
295
x
|
158
x
|
-20.3
x
|
-15.5
x
|
FCF Yield
|
3.17%
|
-1.32%
|
0.34%
|
0.63%
|
-4.93%
|
-6.47%
|
Price to Book
|
1.91
x
|
1.54
x
|
4.78
x
|
2.61
x
|
1.86
x
|
1.53
x
|
Nbr of stocks (in thousands)
|
31,178
|
31,188
|
31,198
|
30,925
|
30,925
|
30,925
|
Reference price
2 |
9,160
|
7,900
|
26,550
|
15,200
|
11,550
|
8,950
|
Announcement Date
|
19-03-15
|
20-03-13
|
21-03-12
|
22-03-18
|
23-03-17
|
24-03-15
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
104,043
|
125,259
|
132,976
|
134,399
|
156,677
|
154,825
|
EBITDA
1 |
15,833
|
20,337
|
21,817
|
18,617
|
25,480
|
10,872
|
EBIT
1 |
6,848
|
11,276
|
16,140
|
12,612
|
17,179
|
979.6
|
Operating Margin
|
6.58%
|
9%
|
12.14%
|
9.38%
|
10.96%
|
0.63%
|
Earnings before Tax (EBT)
1 |
4,797
|
10,619
|
6,205
|
24,234
|
15,234
|
4,895
|
Net income
1 |
6,337
|
8,504
|
6,412
|
19,094
|
12,445
|
4,671
|
Net margin
|
6.09%
|
6.79%
|
4.82%
|
14.21%
|
7.94%
|
3.02%
|
EPS
2 |
203.9
|
272.7
|
205.6
|
613.8
|
402.0
|
108.4
|
Free Cash Flow
1 |
9,160
|
-3,232
|
2,775
|
2,959
|
-18,487
|
-20,502
|
FCF margin
|
8.8%
|
-2.58%
|
2.09%
|
2.2%
|
-11.8%
|
-13.24%
|
FCF Conversion (EBITDA)
|
57.85%
|
-
|
12.72%
|
15.89%
|
-
|
-
|
FCF Conversion (Net income)
|
144.54%
|
-
|
43.28%
|
15.5%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-15
|
20-03-13
|
21-03-12
|
22-03-18
|
23-03-17
|
24-03-15
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
33.41
|
39.77
|
35.31
|
40.36
|
39.53
|
41.48
|
48.2
|
39.5
|
31.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
3.336
|
5.935
|
2.595
|
8.136
|
6.19
|
0.4099
|
8.257
|
0.4194
|
-4.374
|
Operating Margin
|
9.99%
|
14.92%
|
7.35%
|
20.16%
|
15.66%
|
0.99%
|
17.13%
|
1.06%
|
-13.84%
|
Earnings before Tax (EBT)
1 |
-
|
5.453
|
2.373
|
7.554
|
-
|
-0.2469
|
8.732
|
2.22
|
-4.682
|
Net income
1 |
4.951
|
3.984
|
1.884
|
5.535
|
-
|
-0.082
|
7.064
|
1.361
|
-5.498
|
Net margin
|
14.82%
|
10.02%
|
5.34%
|
13.72%
|
-
|
-0.2%
|
14.66%
|
3.44%
|
-17.4%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-12
|
22-03-02
|
22-05-13
|
22-08-16
|
22-11-14
|
23-03-02
|
23-05-09
|
23-08-11
|
23-11-14
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
3,711
|
-
|
-
|
-
|
17,949
|
40,053
|
Net Cash position
1 |
-
|
1,122
|
9,915
|
3,023
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.2344
x
|
-
|
-
|
-
|
0.7044
x
|
3.684
x
|
Free Cash Flow
1 |
9,160
|
-3,232
|
2,775
|
2,959
|
-18,487
|
-20,502
|
ROE (net income / shareholders' equity)
|
4.36%
|
5.34%
|
3.79%
|
10.7%
|
6.62%
|
2.45%
|
ROA (Net income/ Total Assets)
|
2.39%
|
3.58%
|
4.27%
|
2.91%
|
3.76%
|
0.22%
|
Assets
1 |
265,180
|
237,234
|
150,296
|
657,150
|
330,848
|
2,119,215
|
Book Value Per Share
2 |
4,793
|
5,146
|
5,552
|
5,834
|
6,196
|
5,863
|
Cash Flow per Share
2 |
421.0
|
593.0
|
1,621
|
1,620
|
1,007
|
264.0
|
Capex
1 |
2,545
|
8,791
|
7,698
|
11,850
|
25,933
|
7,747
|
Capex / Sales
|
2.45%
|
7.02%
|
5.79%
|
8.82%
|
16.55%
|
5%
|
Announcement Date
|
19-03-15
|
20-03-13
|
21-03-12
|
22-03-18
|
23-03-17
|
24-03-15
|
|
1st Jan change
|
Capi.
|
---|
| +74.97% | 355M | | +31.16% | 588B | | -3.42% | 364B | | +18.02% | 326B | | +4.27% | 285B | | +14.98% | 239B | | +9.93% | 210B | | -7.73% | 200B | | +8.12% | 167B | | -1.42% | 161B |
Other Pharmaceuticals
|